1 Ultra-High-Yield Healthcare Stock to Buy Hand Over Fist

Income investors have both good and not-so-good options in the healthcare sector.
The healthcare sector isn’t the first place income investors turn to find high dividend yields. Of the 11 S&P 500 sectors ranked based on average dividend yield, healthcare comes in eighth.
Plenty of healthcare stocks, though, pay juicy dividends. Some are good picks, but others aren’t. Here’s one ultra-high-yield healthcare stock to buy hand over fist — and one to avoid.
Buy Pfizer
Some investors might think Pfizer (PFE -0.31%) is a healthcare stock to avoid rather than buy hand over fist. That view is understandable if you only look at the drugmaker’s recent history. Pfizer’s share price has plunged over 50% from the peak set in late 2021. Although the stock has risen this year, it’s barely in positive territory with a meager gain that lags well behind the S&P 500’s strong return.
The primary culprit behind Pfizer’s dismal performance is its COVID-19 vaccine Comirnaty. In 2022, Comirnaty generated sales of $37.8 billion. Pfizer expects the vaccine to rake in only $5 billion in 2024.
To make matters worse, Pfizer faces a looming patent cliff. Kidney cancer drug Inlyta and autoimmune disease drug Xeljanz lose patent exclusivity next year. Patents for breast cancer drug Ibrance and prostate cancer drug Xtandi expire in 2027. Blood thinner Eliquis faces biosimilar competition by 2028. Rare disease drug Vyndaqel goes off-patent in 2028, assuming Pfizer wins a patent term extension.
Should all of this make income investors leery about Pfizer’s ultra-high forward dividend yield of 5.66%? I don’t think so. Instead, I view Pfizer as a smart pick for anyone seeking income. The drugmaker puts maintaining and growing its dividend at the top of its capital allocation priorities.
More importantly, Pfizer’s future should be brighter than it looks at first glance. The company returned to year-over-year revenue growth in the second quarter of 2024 for the first time since the fourth quarter of 2022. Management expects to deliver solid growth in the second half of the decade thanks to multiple new products on the market.
Pfizer’s pipeline also includes some potentially huge winners. Its experimental obesity drug danuglipron looks promising. The company advanced three new cancer therapies into late-stage testing this year: sigvotatug vedotin, atirmociclib, and mevrometostat.
Many investors seem to think Pfizer will continue languishing with its shares trading at only 10.5 times forward earnings. I believe this is an attractive valuation for a company with a long track record of resilience, improving growth prospects, and a fantastic dividend.
Avoid Walgreens Boots Alliance
I used a stock screener to identify the healthcare stocks with the highest dividend yields. Only one stock ranked higher than Walgreens Boots Alliance (WBA -6.89%). The pharmacy retailer and wholesaler’s forward dividend yield tops 9%.
Should income investors jump aboard the Walgreens train to get that sky-high dividend? I wouldn’t advise doing so.
Walgreens’ problems make Pfizer look like a superstar in comparison. The pharmacy stock has plunged nearly 80% below its three-year high. Walgreens has lost more than half of its market cap in 2024 alone.
While Pfizer’s financials are improving, Walgreens’ financials are headed in the wrong direction. The company’s adjusted earnings per share dropped 40.8% year over year in its latest quarter. Walgreens expects even lower earnings in fiscal 2025.
CEO Tim Wentworth said in the company’s recent earnings conference call that roughly 2,000 of Walgreens’ more than 8,000 stores aren’t profitable. That’s not good.
Could Walgreens turn things around? Maybe. The company expects to close around 1,200 unprofitable stores over the next three years. Walgreens is also cutting costs in other ways.
However, I doubt income investors will have a warm-and-fuzzy feeling about Walgreens’ dividend. When asked about the dividend in the earnings call, Wentworth replied, “[W]e will absolutely continue to monitor and make changes to our capital allocation, including better aligning our dividend with our long-term earnings power if we believe that’s the appropriate thing to do.” That sounds like a dividend cut could be on the way to me.
Some aggressive investors seeking turnaround plays might find Walgreens worthy of consideration. But for other investors, it’s probably best to stay on the sidelines with this stock.
Hand Over Fist
Here is the short version of Hand Over Fist, including what to check first and what to ignore.
What should beginners know about Hand Over Fist?
Start with the basics covered above, apply one change at a time, and note what happens. That way you can tell which step actually made the difference instead of guessing.
How long does Hand Over Fist take to show results?
It depends on your starting point. Most readers see a clear difference after four to six weeks of consistent work, and sooner when they track results weekly.
Anyone weighing Hand Over Fist should compare at least two realistic options before deciding. In practice, Hand Over Fist works best when the basics are handled before anything else. A quick note on Hand Over Fist: the follow-up matters as much as the first decision. If Hand Over Fist feels overwhelming, start with the smallest step that produces a visible result.






Related reading
For background context, see MedlinePlus.
Mistakes that cost time and money
The most common mistake with Hand Over Fist is treating the first option you find as the only option. Comparison is not busywork: differences in scope, support, and timing often matter more than the headline number.
The second mistake is ignoring the follow-up. Whatever you choose, plan how you will check that it worked. A quick review after two weeks catches problems while they are still cheap to fix, and it turns Hand Over Fist from a one-time decision into something you can improve.
What to check before you start
Before committing time or money to Hand Over Fist, it helps to know what a good outcome looks like. Write down the result you actually need, the budget you can live with, and the deadline you are working against. Those three answers rule out most of the options that look attractive but do not fit your situation.
Next, look at the details that are easy to miss: what is included, what costs extra, and what happens when something goes wrong. Ask directly about timelines and follow-up. A clear answer is usually a better sign than a low price, because Hand Over Fist is rarely a one-off purchase of attention.






